BioSpace News Archive

Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the company’s novel MS Disease Activity (MSDA) test.

Hackensack Meridian John Theurer Cancer Center investigators participated in the large phase III multicenter SHINE study, which reported that using the drug ibrutinib (Imbruvica®) in combination with standard bendamustine and rituximab (BR) therapy as initial treatment for mantle cell lymphoma (MCL) slowed disease growth by 52% in older people newly diagnosed with the disease.

According to Vision Research Reports, the tissue processing systems market size was valued at US$ 320 million in 2020 and expected to reach US$ 570 million by 2030, expanding at a CAGR of 5.1% from 2021 to 2030.

The vascular access devices market size was valued at US$ 6.2 billion in 2020 and is projected to expand at a CAGR of 6.1% from 2021 to 2030.

Seagen Inc. (Nasdaq: SGEN) today announced results from a presentation by the Children’s Oncology Group (COG) of a phase 3 trial (AHOD1331) evaluating ADCETRIS® (brentuximab vedotin) in children and young adults with high-risk, previously untreated classical Hodgkin lymphoma (cHL).

Freeline Therapeutics Holdings plc announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggregate of 270,000 and 191,850 of the Company’s ordinary shares, respectively.

Arcellx, Inc. (NASDAQ: ACLX), today announced new positive clinical data from the ongoing Phase 1 expansion study of its novel, autologous, CART-ddBCMA therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Amgen (NASDAQ:AMGN) will present at the 2022 Jefferies Healthcare Conference at 9:30 a.m. ET on Wednesday, June 8, 2022.

Blueprint Medicines Corporation announced that, effective on June 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 47,587 shares of its common stock and an aggregate of 23,787 restricted stock units to twenty-seven new employees under Blueprint Medicines’ 2020 Inducement Plan.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.